RxDoctor Payments Data

Kristina Deconti, APRN

Family · East Hartford, CTNPI 1003491036

Payments from drug & device makers

$8,043in general payments, 2019–2025

Across 370 payments — averaging $21.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • AbbVie$1K
  • Boehringer Ingelheim$643
  • Amgen$540
  • Pfizer$427
  • Novo Nordisk$356
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$8,041100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC51$1,081
AbbVie42$1,078
Boehringer Ingelheim32$643
Amgen27$540
Pfizer19$427
Novo Nordisk18$356
GSK14$312
AstraZeneca(2 entities)18$297
Exact Sciences8$219
Abbott7$178
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$158
Bayer7$157
Cequr Corporation3$150
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC7$145
Novartis5$133
Lifescan, Inc.8$132
Mallinckrodt Hospital Products Inc.6$126
Sanofi-aventis U.S. LLC7$123
Otsuka America Pharmaceutical, Inc.5$106
Harmony Biosciences LLC5$106
Xeris Pharmaceuticals, Inc.5$98
Mannkind Corporation3$89
Endo Pharmaceuticals Inc.5$83
Corcept Therapeutics4$82
Verona Pharma, Inc.3$63
Neurocrine Biosciences, Inc.2$63
Amryt Pharma Holdings Ltd3$63
Shield Therapeutics Inc3$62
Alvogen Inc3$59
BETA Bionics, Inc.2$58
Almatica Pharma LLC3$57
Lundbeck LLC3$55
Kyowa Kirin, Inc.3$52
Astellas Pharma US Inc2$50
IBSA Pharma Inc.2$43
Ultragenyx Pharmaceutical Inc.2$42
Indivior Inc.1$39
Insulet Corporation2$36
Medtronic2$32
Viatris Specialty LLC1$31
Tandem Diabetes Care, Inc.1$29
E.r. Squibb & Sons, L.L.C.1$28
Teva Pharmaceuticals USA, Inc.1$28
Acerus Pharmaceuticals Corporation2$27
Biogen1$25
Dexcom, Inc.1$25
Antares Pharma, Inc.1$23
Takeda Pharmaceuticals U.S.A., Inc.1$23
Ascendis Pharma Endocrinology Inc1$21
Phathom Pharmaceuticals, Inc.1$21
Pulmonx Corporation1$21
Zealand Pharma US, Inc.1$20
Amarin Pharma, Inc.1$20
Actelion Pharmaceuticals US, Inc.1$20
Chiesi USA, Inc.1$19
Rhythm Pharmaceuticals, Inc.1$18
Qiagen, LLC1$17
Kowa Pharmaceuticals America, Inc.1$12
Progenics Pharmaceuticals, Inc.1$12
Philips North America LLC1$11

How this compares

$8,043 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$27,356
Medicare patients
133
Services billed
402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$32,637
EliquisApixaban12$12,429
Albuterol Sulfate HfaAlbuterol Sulfate51$1,195
FenofibrateFenofibrate Nanocrystallized21$581
Oxycodone Hcl27$578
Atorvastatin Calcium71$532
Amlodipine Besylate63$532
Fluticasone Propionate22$398
Gabapentin19$345
Famotidine13$300
Lisinopril41$291
Metformin Hcl44$270
Metoprolol Succinate18$269
Escitalopram Oxalate38$243
Losartan Potassium26$156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$356$32,63732 claims
PfizerEliquis$427$12,42912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.

Other family in East Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →